-
Foundation Medicine Set For 'Material Upside,' Cowen Says In Bullish Initiation
Thursday, February 15, 2018 - 5:56pm | 430Read More...Foundation Medicine Inc (NASDAQ: FMI), a manufacturer of genomic analysis diagnostics for solid and circulating cancer, is uniquely positioned in comprehensive cancer profiling, a Cowen analyst said. The Analyst Cowen analyst Doug Schenkel initiated coverage of Foundation Medicine...
-
Cowen: Hologic Is A Relatively Cheap Stock Overdue For Upside
Monday, December 11, 2017 - 12:09pm | 508Read More...Valuation of Hologic, Inc. (NASDAQ: HOLX) — which manufactures diagnostic products, medical imaging systems and surgical products — is attractive, according to a Cowen analyst. The Analyst Cowen analyst Doug Schenkel upgraded shares of Hologic from Market Perform to...
-
Analyst Leaves Exact Sciences CEO Meeting With 'Fortified Confidence' Despite Recent Controversy
Tuesday, May 16, 2017 - 3:23pm | 549Read More...Following a series of investor meetings with EXACT Sciences Corporation's (NASDAQ: EXAS) CEO and chief financial officer, Cowen said it has come back with fortified confidence in the outlook for upside relative to current Street financial expectations. Not All Are Optimistic This is in...
-
Cowen: Becton Dickinson Well Positioned Relative To 2016, 2017 Expectations
Monday, August 15, 2016 - 12:35pm | 298Read More...Cowen said Becton Dickinson and Co (NYSE: BDX) is well-positioned relative to F2016 and F2017 revenue and EPS expectations, while reiterating its Outperform rating and $185 price target on the stock. "The FQ4:2016 Y/Y organic revenue growth rate is expected to be notably higher than those...
-
Genomic Health: A Prostate Play Helping Investors Get Ahead Of The Curve?
Thursday, November 19, 2015 - 2:31pm | 344Read More...The share price of Genomic Health, Inc. (NASDAQ: GHDX) has appreciated 36.28 percent over the past month, from $21.42 on October 20. Cowen and Company’s Doug Schenkel upgraded the rating on the company from Market Perform to Outperform, while raising the price target from $27 to $35....
-
Cowen Downgrades Hologic
Monday, December 2, 2013 - 2:03pm | 167Read More...Cowen and Company analyst Doug Schenkel downgraded Hologic, Inc. (NASDAQ: HOLX) from Outperform to Market Perform and lowered the price target from $25.50 to $24. Schenkel noted that Hologic is "not on the cusp of revenue re-acceleration" with growth headwinds including legacy 2D mammography...
